Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Misses Expectations By $0.29 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.29), FiscalAI reports. The firm had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $2.27 million.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio received FDA accelerated approval for VOCERYQ, its first commercial product and the first FDA-approved plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). In the FDA’s analysis of 26 patients with at least three prior-year surgeries, 27% required no surgery in the 12 months after treatment; the company also cited durable responses and a generally favorable tolerability profile.
• Inovio is preparing a U.S. launch, with product availability expected about 60 days after approval and full field deployment targeted for Q1 2027. Management estimates at least 25,000 adult RRP patients in the U.S. and says its planned field team is designed to reach 90% of patient potential, though payer coverage and uptake estimates are based on company research.
• VOCERYQ’s accelerated approval requires a confirmatory study to verify clinical benefit, and continued approval may depend on its results. Inovio plans to submit a draft protocol by year-end and aims to agree on a final design with the FDA by mid-2027; the study is expected to include at least 50 adult and pediatric patients.
• After an equity offering that generated about $80.5 million in net proceeds, plus quarter-end cash and subsequent warrant exercises, Inovio expects to fund operations into late Q4 2027, excluding potential VOCERYQ revenue or future fundraising. The company reported Q3 operating expenses of $19.8 million, down from $21.2 million a year earlier; its $49.2 million net loss was primarily driven by a non-cash warrant fair-value adjustment.

Inovio Pharmaceuticals Trading Down 4.0%

Shares of INO stock traded down $0.06 on Tuesday, reaching $1.45. 14,207,659 shares of the company’s stock were exchanged, compared to its average volume of 4,845,135. Inovio Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $2.72. The stock has a market capitalization of $149.93 million, a PE ratio of -1.59 and a beta of 1.71. The company’s fifty day simple moving average is $1.17 and its 200 day simple moving average is $1.27.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $8.00 price target (up from $3.00) on shares of Inovio Pharmaceuticals in a report on Friday. Piper Sandler restated an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright set a $5.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 2nd. Finally, Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $5.67.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.